| Literature DB >> 2179764 |
L F Kastrukoff1, J J Oger, S A Hashimoto, S L Sacks, D K Li, M R Palmer, R A Koopmans, A J Petkau, J Berkowitz, D W Paty.
Abstract
A randomized, double-blind, placebo-controlled, noncrossover trial determined the efficacy of lymphoblastoid interferon (IFN) in chronic progressive multiple sclerosis (CP MS). Fifty patients received 5 X 10(6) IU IFN subcutaneously daily for 6 months while 50 received placebo. After 2 years, there were no significant differences between the 2 groups based on clinical evaluations and quantitative MRI analysis of the brain, although a trend was observed in the IFN group. Clinically, the IFN group was worse at 1 and 3 months and improved at 6 to 18 months, when compared with the placebo group. Results of MRI evaluations of the brain at 6 months support this trend. This trend likely resulted from a subpopulation of 10 IFN-treated patients, characterized by a higher women:men ratio and a lower EDSS score at entry into the trial. We cannot recommend lymphoblastoid IFN as treatment for CP MS at this time.Entities:
Mesh：
Substances：
Year: 1990 PMID： 2179764 DOI： 10.1212/wnl.40.3_part_1.479
Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910